Promontory Therapeutics

Promontory Therapeutics is a privately held clinical-stage pharmaceutical company focused on small molecule immunotherapy. The company’s lead candidate, PT-112, is the first pyrophosphate small molecule conjugate in oncology, featuring a unique pleiotropic mechanism of action that induces immunogenic cell death (ICD), leading to an adaptive immune response.